Expedite translation of regenerative applications from bench to commercialization using a non-viral, cGMP-compliant cell engineering platform that provides the necessary performance and scalability while overcoming regulatory hurdles. The MaxCyte delivery platform harnesses the power of primary cells through high performance cell engineering to create cell-based therapies with increased therapeutic potential.
Pulmonary arterial hypertension (PAH) is a progressive and ultimately lethal disease characterized by a persistent elevation in pulmonary arterial pressure due to narrowing of arterioles and loss of pulmonary microvessels. Cell-based therapies offer the potential to repair and regenerate the lung microcirculation.
Endothelial progenitor cells (EPC) have been intensively studied and are felt to have great potential for cardiovascular regenerative applications, however initial animal studies administering unmodified EPCs exhibited insufficient potency to warrant clinical development. MaxCyte’s cell engineering platform has enabled development and clinical translation (PHACeT Clinical Trial) of a stem cell therapy with increased potency in which EPCs are engineered to express endothelial nitric oxide synthase (eNOS-EPCs).
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter